Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 1999

View Archived Issues

UC Irvine and NeoTherapeutics enter research and licensing agreement

Myriad Genetics identifies diabetes gene

Antex Biologics and SB restructure agreement

Novartis receives approvable letter from FDA for Trileptal

Jak2 tyrosine kinase inhibitor prevents cell proliferation in ALL cells in vitro

Positive inotropic activity of EMD-57033 is maintained during MI

Novel natriuretic peptide is a candidate for treating CHF

Conivaptan effectively and safely reverses hyponatremia in patients with CHF

Roche presents antiproliferative retiferol derivatives particularly useful for psoriasis

Calcium channel blockers described in recently issued patent by Warner-Lambert

Protein farnesyltransferase inhibitors developed at Schering-Plough

New compounds for inflammatory conditions from Genetics Institute act by inhibiting PLA2

ECCO 10 presentation for a novel VEGF receptor TK inhibitor

New prescribing information for flutamide

Orally active, non-neurotoxic anticonvulsants and EAA antagonists designed by K & K Biosciences

Results of phase III becaplermin study in pressure ulcers are inconsistent with phase II findings

More brain GABA-A receptor ligands in the Neurogen pipeline

Licensing opportunity from NIH: thiazepine inhibitors of HIV-1 integrase

Further efforts in the area of 2-pyridone antibacterials described by Abbott at ICAAC

IntraDose featured in several ECCO 10 presentations; clinical results consistently positive

Clinical candidate selected by Wakunaga from series of antibacterial 8-methylquinolones

J-110441: a broad-spectrum carbapenem-derived beta-lactamase inhibitor designed at Banyu

Gilead's once-daily anti-HIV agent effective and safe in patients, as reported at ICAAC

Duloxetine safety and pharmacokinetics determined in healthy volunteers

Ondansetron effectively controls tardive dyskinesia and improves symptoms of psychosis

EntreMed's first phase I study of Endostatin now enrolling patients

New Lilly compounds LY-314177 and LY-311912 active against influenza A infections in mice

Identification of tetracycline resistance reverser reported at ICAAC by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...